Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
13.26
+0.53 (4.16%)
Nov 21, 2024, 1:03 PM EST - Market open
Pliant Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Pliant Therapeutics stock have an average target of 40.5, with a low estimate of 33 and a high estimate of 45. The average target predicts an increase of 205.43% from the current stock price of 13.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PLRX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +186.58% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +186.58% | Sep 13, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $33 | Buy | Initiates | $33 | +148.87% | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $38 | Strong Buy | Maintains | $36 → $38 | +186.58% | Aug 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 8, 2024 |
Financial Forecast
Revenue This Year
446.25K
from 1.58M
Decreased by -71.76%
Revenue Next Year
3.06M
from 446.25K
Increased by 585.71%
EPS This Year
-3.71
from -2.75
EPS Next Year
-4.16
from -3.71
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.2M | 21.0M | 21.0M | ||
| Avg | 446,250 | 3.1M | 6.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 99.4% | 4,605.9% | 586.3% | ||
| Avg | -71.8% | 585.7% | 94.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.66 | -3.27 | -3.76 | ||
| Avg | -3.71 | -4.16 | -4.36 | ||
| Low | -3.69 | -5.13 | -6.51 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.